Molecular guide system peptides and uses thereof

Patent metadata

Field	Value
Publication number	US-11965004-B2
Application number	US-201816629799-A
Country	US
Kind code	B2
Filing date	Jul 10, 2018
Priority date	Jul 10, 2017
Publication date	Apr 23, 2024
Grant date	Apr 23, 2024

Abstract

Disclosed are compositions comprising an antibody conjugated to one or more molecular guidance system (MGS) peptides. Disclosed are methods of treating a subject in need thereof comprising administering to the subject in need thereof an effective amount of an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target involved in the disease process. Disclosed are methods of targeting an intracellular target comprising administering an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target.

First claim

What is claimed is:

1. A composition comprising an antibody conjugated to one or more molecular guidance system (MGS) peptides, directly or via a linker, wherein the one or more MGS peptides are selected from the group consisting of SEQ ID NOs: 2, 3, 20-22, and 38-41.

2. The composition of claim 1 , wherein the antibody targets an intracellular target.

3. The composition of claim 1 , wherein the antibody is a monoclonal antibody.

4. The composition of claim 3 , wherein the monoclonal antibody is an anti-Ras monoclonal antibody.

5. The composition of claim 1 , wherein the one or more MGS peptides consists of SEQ ID NO: 38.

6. The composition of claim 1 , wherein the one or more MGS peptides localize to an intracellular target selected from the lysosome, golgi apparatus, endoplasmic reticulum, cytoplasm, or nucleus.

7. The composition of claim 1 , wherein the antibody is conjugated to the one or more MGS peptides via a linker.

8. The composition of claim 7 , wherein the linker comprises polyethylene glycol (PEG).

9. A molecular guidance system (MGS) peptide selected from the group consisting of SEQ ID NOs: 2, 3, 20-22, and 38-41.

10. A method of targeting an intracellular target in a cell in vitro or in a subject, comprising contacting the cell with or administering to the subject a composition according to claim 1 , wherein the antibody targets an intracellular target.

11. The method of claim 10 , wherein the intracellular target is the lysosome, golgi apparatus, endoplasmic reticulum, cytoplasm, or nucleus.

12. A method of treating a subject having a disease in need thereof comprising administering to the subject in need thereof an effective amount of the composition of claim 1 , wherein the antibody targets an intracellular target involved in the disease process.

13. The method of claim 12 , wherein the subject in need thereof has an infectious disease, cancer, diabetes, a neurological or neurodegenerative disease, a genetically-inherited disease, or has been exposed to a bioterrorism agent.

Assignees

• Stanford Res Inst Int

Inventors

• Brown Kathlynn C
• Collins Nathan
• Li Shunzi “Susan”
• Allred Curtis
• Chung Keen
• Mcguire Michael

Classifications

• C07K2319/01

  containing a localisation/targetting motif · CPC title

• C07K2317/77

  Internalization into the cell · CPC title

• G01N2500/10

  involving cells · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title